Search results for " STEM"

showing 10 items of 2170 documents

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem‐cell transplantation

2011

Antifungal prophylaxis for allogeneic haematopoietic stem-cell transplant (alloHCT) recipients should prevent invasive mould and yeast infections (IFIs) and be well tolerated. This prospective, randomized, open-label, multicentre study compared the efficacy and safety of voriconazole (234 patients) versus itraconazole (255 patients) in alloHCT recipients. The primary composite endpoint, success of prophylaxis, incorporated ability to tolerate study drug for ≥100 d (with ≤14 d interruption) with survival to day 180 without proven/probable IFI. Success of prophylaxis was significantly higher with voriconazole than itraconazole (48·7% vs. 33·2%, P 10%) treatment-related adverse events were vom…

AdultMalemedicine.medical_specialtyAntifungal AgentsAdolescentItraconazoleazolesstem-cell transplantPharmacologyBiologyAspergillosisGastroenterologyYoung AdultInternal medicineAmphotericin BmedicineHumansTransplantation Homologousyeast infectionsProspective StudiesChildAdverse effectAgedVoriconazoleHaematological MalignancyHematopoietic Stem Cell TransplantationHematologyMiddle AgedTriazolesmedicine.diseaseinvasive fungal diseaseTransplantationPyrimidinesMycosesmould infectionsFemaleVoriconazoleLiver functionItraconazoleFluconazolemedicine.drugBritish Journal of Haematology
researchProduct

Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Res…

2010

Caspofungin at standard dose was evaluated as first-line monotherapy of mycologically documented probable/proven invasive aspergillosis (IA) (unmodified European Organisation for Research and Treatment of Cancer/Mycosis Study Group criteria) in allogeneic hematopoietic SCT patients. The primary efficacy end point was complete or partial response at end of caspofungin treatment. Response at week 12, survival and safety were additional end points. Enrollment was stopped prematurely because of low accrual, with 42 enrolled and 24 eligible, giving the study a power of 85%. Transplant was from unrelated donors in 16 patients; acute or chronic GVHD was present in 15. In all, 12 patients were neut…

AdultMalemedicine.medical_specialtyAntifungal AgentsDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentGraft vs Host DiseaseHematopoietic stem cell transplantationAspergillosischemistry.chemical_compoundEchinocandinsLipopeptidesYoung AdultPharmacotherapyCaspofunginInternal medicineMedicineAspergillosisHumansTransplantation HomologousaspergillosiscaspofunginAdverse effectSurvival rateAgedallogeneicTransplantationbusiness.industryHematopoietic Stem Cell Transplantationhematopoietic SCTHematologyMiddle Agedmedicine.diseaseSurgeryCalcineurinTransplantationEuropeSurvival RateTreatment OutcomechemistryDrug Therapy CombinationFemaleCaspofunginbusinessBone marrow transplantation
researchProduct

Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobil…

2005

The optimal approach to obtain an adequate graft for transplantation in patients with poor peripheral blood stem cell (PBSC) mobilization remains unclear. We retrospectively assessed the impact of different strategies of second-line stem cell harvest on the transplantation outcome of patients who failed PBSC mobilization in our institution. Such patients were distributed into three groups: those who proceeded to steady-state bone marrow (BM) collection (group A, n = 34); those who underwent second PBSC mobilization (group B, n = 41); those in whom no further harvesting was carried out (group C, n = 30). PBSC harvest yielded significantly more CD34+ cells than BM collection. Autologous trans…

AdultMalemedicine.medical_specialtyAntigens CD34Bone Marrow CellsCell CountTransplantation AutologousInternal medicineGranulocyte Colony-Stimulating FactorMedicineAutologous transplantationHumansLeukapheresisHematopoietic Stem Cell MobilizationAgedBone Marrow TransplantationRetrospective StudiesTransplantationPeripheral Blood Stem Cell TransplantationHematologyBlood Cellsbusiness.industryHematologyLeukapheresisMiddle AgedHematopoietic Stem Cell MobilizationGranulocyte colony-stimulating factorSurgeryTransplantationmedicine.anatomical_structureTreatment OutcomeHematologic NeoplasmsFemaleBone marrowStem cellbusinessBone marrow transplantation
researchProduct

Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findin…

2018

Patients with primary refractory or relapsed acute myeloid leukemia (RR-AML) have very poor prognosis. Due to limited treatment options, some patients are treated with hypomethylating agents (HMAs) due to their tolerability. Little is known about the role of allogeneic hematopoietic stem cell transplantation (HSCT) following HMA therapy in this setting. We retrospectively analyzed an international cohort of 655 RR-AML patients who received HMA therapy to study patterns and outcomes with HSCT. Only 37 patients (5.6%) patients underwent HSCT after HMA therapy. The conditioning regimen was myeloablative in 57% and nonmyeloablative in 43%. Patients received matched unrelated donor, matched sibl…

AdultMalemedicine.medical_specialtyAntimetabolites AntineoplasticTransplantation ConditioningSurvivalmedicine.medical_treatmentSalvage therapyGraft vs Host DiseaseHypomethylating agentsHematopoietic stem cell transplantationTransplant03 medical and health sciences0302 clinical medicineRefractoryAMLimmune system diseasesInternal medicinehemic and lymphatic diseasesmedicineHumansTransplantation HomologousSurvival analysisAgedRetrospective StudiesSalvage TherapyTransplantationAML; Hypomethylating agents; Survival; Transplant; Adult; Aged; Antimetabolites Antineoplastic; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia Myeloid Acute; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation Homologousbusiness.industryHematopoietic Stem Cell TransplantationRetrospective cohort studyHematologyMiddle AgedSurvival AnalysisLeukemia Myeloid Acutesurgical procedures operativeTolerability030220 oncology & carcinogenesisCohortFemaleTransplantation Conditioningbusiness030215 immunology
researchProduct

Binding of monocytes from normolipidemic hyperglycemic patients with type 1 diabetes to endothelial cells is increased in vitro.

2009

Increased endothelial binding and emigration of monocytes play a dominant role in the pathogenesis of atherosclerosis in diabetes mellitus. Previous studies revealed that hyperlipidemia correlates with monocyte binding in vitro. The aim of this study was to characterize the monocyte-endothelial interaction of leucocytes of hyperglycemic patients with type 1 diabetes but lacking hyperlipidemia. We isolated monocytes from healthy controls and normolipidemic type 1 diabetes patients with elevated levels of HbA1c and quantified monocyte binding by an immunoilluminometric cell adhesion assay. Purity of isolated monocytes was at least 98%. Endothelial binding of monocytes from patients with type …

AdultMalemedicine.medical_specialtyArteriosclerosisEndocrinology Diabetes and MetabolismCell CountMonocytesPathogenesischemistry.chemical_compoundEndocrinologyInternal medicineDiabetes mellitusHyperlipidemiaInternal MedicinemedicineCell AdhesionHumansType 1 diabetesbusiness.industryCD11 AntigensImmunomagnetic SeparationMonocyteAntibodies MonoclonalGeneral Medicinemedicine.diseaseFlow CytometryIn vitroEndothelial stem cellEndocrinologymedicine.anatomical_structureDiabetes Mellitus Type 1GlucoseL-GlucosechemistryHyperglycemiaLuminescent MeasurementsMultivariate AnalysisRegression AnalysisFemaleEndothelium VascularbusinessExperimental and clinical endocrinologydiabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
researchProduct

Seventh nerve palsies may be the only clinical sign of small pontine infarctions in diabetic and hypertensive patients

2002

Backgroud: Small brainstem infarctions are increasingly recognized as a cause of isolated ocular motor and vestibular nerve palsies in diabetic and/or hypertensive patients. This raises the question whether there are also isolated 7th nerve palsies due to pontine infarctions in patients with such risk factors for the development of cerebrovascular diseases. Methods: Over an 11-year-period, we retrospectively identified 10 diabetic and/or hypertensive patients with isolated 7th nerve palsies and electrophysiological abnormalities indicating pontine dysfunction. All patients had examinations of masseter and blink reflexes, brainstem auditory evoked potentials, direct current electro-oculograp…

AdultMalemedicine.medical_specialtyBrain Stem InfarctionsNeurologyFunctional LateralityDiabetes ComplicationsOcular Motility DisordersPonsInternal medicineNeural PathwaysDiabetes MellitusVestibulocochlear Nerve DiseasesmedicineHumansCranial nerve diseaseStrokeAgedRetrospective StudiesParesisbusiness.industryMiddle AgedVestibular nervemedicine.diseaseMagnetic Resonance ImagingFacial nerveFacial paralysisSurgeryFacial NerveNeurologyBasilar ArteryHypertensionCardiologyFemaleDisease SusceptibilityNeurology (clinical)Facial Nerve Diseasesmedicine.symptombusinessJaw jerk reflexJournal of Neurology
researchProduct

Biomarker profile predicts clinical efficacy of extracorporeal photopheresis in steroid‐resistant acute and chronic graft‐vs‐host disease after allog…

2021

We conducted a multicenter interventional study to assess the efficacy of Therakos ECP to treat steroid-resistant graft-vs-host disease (SRes-GVHD) after allogeneic HSCT and to identify biomarkers of GVHD response. A total of 62 patients were treated for acute SRes-GVHD (n = 37) or chronic SRes-GVHD (n = 25). Median time to best response was 35 days (range, 28-85) and 90 days (range, 27-240) in acute and chronic SRes-GVHD, respectively. Overall, 27 patients (72.9%) with SRes-aGVHD responded to treatment (40.5% CR and 32.4% PR). The response rate was significantly higher in grade I-II than in grade III-IV aGVHD (100% vs 50.0%, respectively, P-value = .001). In chronic SRes-GVHD, 22 patients …

AdultMalemedicine.medical_specialtyCD3Graft vs Host DiseaseDisease030204 cardiovascular system & hematologyT-Lymphocytes RegulatoryGastroenterologyYoung Adult03 medical and health sciences0302 clinical medicineimmune system diseasesInternal medicineExtracorporeal PhotopheresismedicineHumansTransplantation HomologousProspective StudiesIL-2 receptorAgedResponse rate (survey)biologybusiness.industryHematopoietic Stem Cell TransplantationHematopoietic stem cellHematologyGeneral MedicineMiddle AgedTreatment Outcomesurgical procedures operativemedicine.anatomical_structurePhotopheresisbiology.proteinCytokinesBiomarker (medicine)FemaleSteroidsbusinessBiomarkersCD8030215 immunologyJournal of Clinical Apheresis
researchProduct

Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria phenotype in patients with splanchnic vein thrombosis

2014

Abstract Introduction Splanchnic vein thrombosis (SVT) is a serious complication in patients with paroxysmal nocturnal hemoglobinuria (PNH). Mutant PNH clones can be associated with an increased risk of SVT even in the absence of overt disease, but their prevalence in non-selected SVT patients remains unknown. Materials and Methods Patients with objective diagnosis of SVT and without known PNH were tested for the presence of PNH clone using high-sensitivity flow cytometric analysis. Results A total of 202 SVT patients were eligible, 58.4% were males, mean age was 54.6 years (range 17–94), site of thrombosis was portal in 103 patients, mesenteric in 67, splenic in 37, and supra-hepatic in 10…

AdultMalemedicine.medical_specialtyCirrhosisAdolescentParoxysmalHemoglobinuria ParoxysmalHemoglobinuriaGastroenterologyYoung AdultRisk Factorshemic and lymphatic diseasesInternal medicine80 and overmedicineHumansMyeloproliferative neoplasmAgedAged 80 and overVenous Thrombosisbusiness.industryMedicine (all)Splanchnic vein thrombosisHematologyMiddle Agedmedicine.diseaseHematopoietic Stem CellsThrombosisAdolescent; Adult; Aged; Aged 80 and over; Cross-Sectional Studies; Female; Hematopoietic Stem Cells; Hemoglobinuria Paroxysmal; Humans; Male; Middle Aged; Risk Factors; Venous Thrombosis; Young Adult; Hematology; Medicine (all)SurgeryPortal vein thrombosisVenous thrombosisSettore MED/15 - MALATTIE DEL SANGUECross-Sectional StudiesSplanchnic vein thrombosisParoxysmal nocturnal hemoglobinuriaFemaleHemoglobinuriabusiness
researchProduct

Effects of intraocular cefotaxime on the human corneal endothelium

2001

Abstract Purpose To ascertain whether 0.4 mL of cefotaxime 0.25% applied intracamerally causes toxic alteration of the human corneal endothelium. Methods In this prospective randomized masked study, 66 patients had cataract extraction using phacoemulsification, a frown incision, and implantation of a poly(methyl methacrylate) intraocular lens. This was followed by intraocular injection of 0.4 mL of cefotaxime 0.25% or balanced salt solution (BSS®). Contact specular microscopy and photography were performed preoperatively and 1 to 4 days and 3 months postoperatively. Results In the cefotaxime group, the mean endothelial cell count was 2729 cells/mm 2 ± 474 (SD) preoperatively, 2520 ± 462 cel…

AdultMalemedicine.medical_specialtyCorneal endotheliumCefotaximeAnterior Chambermedicine.medical_treatmentCell CountIntraocular lensBalanced salt solutionCefotaximeDouble-Blind MethodLens Implantation IntraocularCorneaOphthalmologymedicineHumansProspective StudiesAgedCell SizeAntibacterial agentAged 80 and overEndophthalmitisPhacoemulsificationbusiness.industryEndothelium CornealPhacoemulsificationMiddle AgedSensory SystemsCephalosporinsEndothelial stem cellOphthalmologymedicine.anatomical_structureFemaleSurgerysense organsbusinessmedicine.drugJournal of Cataract and Refractive Surgery
researchProduct

Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autogra…

2011

Contains fulltext : 95663.pdf (Publisher’s version ) (Closed access) We present results of a phase 3 randomized trial of autografting in chronic lymphocytic leukemia versus observation for responding patients after first- or second-line treatment. The primary objective was to demonstrate that autografting improves the 5-year event-free survival (EFS) from 30% to 50%. There were 223 enrolled patients, 72% men and 28% women, 83% after first and 17% after second-line treatment. Binet stages were progressive A 13%, B 67%, C 20%; at randomization, 59% were in complete remission, and 41% in less than complete remission. Patients were randomized between autografting (n = 112) and observation (n = …

AdultMalemedicine.medical_specialtyCyclophosphamidemedicine.medical_treatmentChronic lymphocytic leukemiaImmunologyHematopoietic stem cell transplantationTransplantation AutologousBiochemistryGastroenterologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansSurvival rateAgedbusiness.industryHazard ratioHematopoietic Stem Cell TransplantationTranslational research Immune Regulation [ONCOL 3]Cell BiologyHematologyMiddle Agedmedicine.diseaseCombined Modality TherapyLeukemia Lymphocytic Chronic B-CellSurgeryFludarabineEuropeSurvival RateTransplantationTreatment OutcomeAlemtuzumabFemalebusinessmedicine.drug
researchProduct